August 12, 2019

Mechanistic insights into how Rituximab attenuates Arthritis: Rituximab (brand name: Ritusan), used to treat bone-related disorders, increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis, via up-regulation of its target genes, 13/August/2019, 12.24 am

Introduction: What they say A study from Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany shows that […]
August 12, 2019

Probiotic-based Chemo-Antibody Therapy (PCAT) targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and in advanced metastatic cancers: A pharmaceutical mixture encompassing Ibrutinib, Rituximab and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 13/August/2019, 12.11 am

Introduction: What they say A study from the Stanford University, Stanford, the University of California, Irvine, Medical Center, Orange, and Kaiser Permanente National Cancer Institute Community Oncology […]